Piaopiao Li

Oct 23, 2024 | jamanetwork.com | Piaopiao Li |Elizabeth Staton |Georgia Davis |Hui Shao

Two newer glucose-lowering medications, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors, have significant cardiorenal benefits and advantages in weight management.1 These medications are not approved for type 1 diabetes (T1D), but some evidence indicates their use in this population.2 This study explored prescribing trends for individuals with T1D prescribed GLP-1RAs and SGLT2 inhibitors.